---
schema_version: "secwatch.filing_event.v1"
accession: "0001420720-25-000018"
form_type: "8-K"
ticker: "IBIO"
cik: "0001420720"
company_name: "iBio, Inc."
filed_at: "2025-04-08T23:59:59+00:00"
generated_at: "2026-05-23T18:58:30.279946+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# iBio reveals preclinical data for IBIO-600 and Activin E antibody combo with semaglutide

## Summary
- IBIO-600 NHP study: half-life 40-52 days, potential human half-life up to 130 days; dose-dependent lean mass increase and fat reduction.
- Activin E monotherapy in obese mice: ~4% weight loss, 18% fat reduction vs placebo after two weeks.
- Activin E + semaglutide combination: 34% total weight loss (9% above semaglutide alone), 72% body fat reduction by DEXA.
- Both candidates target obesity and cardiometabolic diseases; IBIO-600 is anti-myostatin, Activin E induces fat-selective weight loss.

## SEC filing metadata
- accession: 0001420720-25-000018
- form_type: 8-K
- ticker: IBIO
- cik: 0001420720
- company_name: iBio, Inc.
- filed_at: 2025-04-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1420720/000142072025000018/0001420720-25-000018-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1420720/000142072025000018/ibio-20250408x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001420720-25-000018
- JSON: https://secwatch.observer/filing/0001420720-25-000018.json
- Plain text: https://secwatch.observer/filing/0001420720-25-000018.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.